Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.93 |
| ▸ | CA6 | P23280 | 4/20 | 0.93 |
| ▸ | CA7 | P43166 | 4/20 | 0.93 |
| ▸ | CA9 | Q16790 | 4/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.93 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.93 |
| ▸ | CA2 | P00918 | 3/20 | 0.93 |
| ▸ | CA4 | P22748 | 3/20 | 0.93 |
| ▸ | CA5A | P35218 | 3/20 | 0.93 |
| ▸ | F13A1 | P00488 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.93 |
| ▸ | THPO | P40225 | 2/20 | 0.93 |
| ▸ | CA3 | P07451 | 2/20 | 0.93 |
| ▸ | CA1 | P00915 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | PKM | P14618 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | MTOR | P42345 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1459664 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL6021973 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL28288034 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL28177765 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL13741268 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL818184 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL9331554 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL561079 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL9144013 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| SCHEMBL1460244 | 1.00 | CA12 (0.93) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974529-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-9114198-B2 | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| CN-102906159-A | Amine polymers as bile acid sequestrants | RELYPSA INC | 2013-01-30 | — | — | CN | disclosed |
| US-8003123-B2 | Biologically absorbable coatings for implantable devices and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110117161-A9 | BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME | HOSSAINY SYED F A | 2011-05-19 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20080206307-A1 | BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME | HOSSAINY SYED F A | 2008-08-28 | — | — | US | disclosed |
| US-7378106-B2 | Biologically absorbable coatings for implantable devices and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070098758-A1 | Biologically absorbable coatings for implantable devices and methods for fabricating the same | ADVANCED CARDIOVASCULAR SYSTEMS | 2007-05-03 | — | — | US | disclosed |
| US-7169404-B2 | Biologically absorbable coatings for implantable devices and methods for fabricating the same | ADVANCED CARDIOVASULAR SYSTEMS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050143472-A1 | Novel treatment for pathologies associated with oxidative damage | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2005-06-30 | — | — | US | disclosed |
| WO-2003068167-A2 | NOVEL TREATMENT FOR PATHOLOGIES ASSOCIATED WITH OXIDATIVE DAMAGE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117161-A9 | BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME | BMP2, BMP6, GUSB | CA12 70/4885CA6 57/4885CA7 131/4885 |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | CA12 2071/4885CA6 2273/4885CA7 2423/4885 |
| US-20080206307-A1 | BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME | BMP2, BMP6, GUSB | CA12 70/4885CA6 57/4885CA7 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.